Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Email

Consultation on the Development of Experimental Cancer Drugs

A Focused Consultation Service Provided by DTP and CIP

Staff of DCTD's Developmental Therapeutics Program (DTP) and Cancer Imaging Program (CIP) have extensive experience in preclinical development of small molecule, biological, or imaging drugs for cancer. Investigators from academia or small biotech companies can request this consultation service, which may help them to develop:

  • A carefully designed drug discovery strategy for hit-to-lead
  • A tailored approach to nonclinical safety studies guided by sound scientific principles
  • An acceptable plan for Good Manufacturing Practices (GMP) production and other aspects for the clinical grade drug substance and drug product
  • An Investigational New Drug (IND) filing plan with data-supported rationale
  • A better strategy for communication with the Food and Drug Administration (FDA)
  • A more refined application to NExT — the primary route for extramural scientists to access NCI's preclinical and clinical development resources

Request a Consultation

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Consultation on the Development of Experimental Cancer Drugs was originally published by the National Cancer Institute.”

Email